Application

Research Sub CategoryDiabetes - Type 2Metabolic Syndrome

Research CategoryMetabolism

This is a 3-hour assay requiring 20 µL (in duplicate) of rat sample or 10µl (in duplicate) of mouse sample.

Used to detect/quantify: FGF-21

Disclaimer

For research use only. Not for use in diagnostic procedures.

General description

Recent studies have demonstrated that fibroblast growth factor 21 (FGF-21), a liver derived protein, is able to increase glucose uptake, as well as lower plasma triglyceride levels in an insulin-independent manner. FGF-21 suppresses glucagon release, thereby increasing insulin sensitivity, and reduces the amount of insulin production by pancreatic β-cells. Unlike insulin, which works in a rapid, hormone-like manner, FGF-21 activity requires several hours, indicating changes in gene expression. No significant weight gain was observed when FGF-21 was injected into animals, and mice that had been genetically engineered to overexpress FGF-21 weighed less and had less adipose tissue than the normal controls.

Although considerable progress has been made in the understanding of the pathobiology of type 2 diabetes, as well in the development of new compounds for the treatment of diabetic patients, this disease remains a major global health concern. Consequently, Millipore is pleased to offer the Rat/Mouse FGF-21 ELISA kit for the quantification of FGF-21 in rat and mouse serum and plasma samples. The insulin-independent activities of FGF-21, as well as the absence of the weight gain effects of insulin, thiazolidinediones and other anti-diabetic drugs, distinguish it from current insulin-sensitizing drugs, making it a promising therapeutic.

Other Notes

Please contact Technical Service for linearity of dilution.

Specificity

Cross-reactivity to Human FGF-21: 39%

No significant cross-reactivity to the cytokines and metabolic hormones tested was observed.